Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Global healthcare giant Schering-Plough Corporation has launched a new scent-free, alcohol-free formulation of its nasal allergy spray Nasonex in the US.
Subscribe to our email newsletter
Nasonex remains the only once-daily prescription nasal inhaled steroid approved to help prevent most seasonal nasal allergy symptoms, including nasal congestion, in adults and children 12 years of age and older when started two to four weeks prior to allergy season.
It is also the only nasal inhaled steroid approved to treat nasal allergy symptoms, including nasal congestion, in patients as young as two years of age and is the first and only nasal inhaled steroid approved for the treatment of nasal polyps in adults 18 years of age and older.
In a survey of more than 2,000 allergic rhinitis sufferers, 76% of patients said they would choose a scent-free product, when all other attributes, such as safety and efficacy, are equal.
The FDA approved the new scent-free formulation on August 26, 2004 following a review of a new drug application (NDA) supplement and the safety and efficacy data from the original formulation of Nasonex nasal spray.